Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VISTA-knockout NK cells
- Development stage
- Preclinical
- Lead developer
- Nationwide Children's Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
VISTA-knockout NK cells are an experimental adoptive cell therapy being investigated for the treatment of malignant gliomas, including glioblastoma multiforme (GBM). Developed by researchers at Nationwide Children's Hospital, these NK cells are modified using CRISPR/Cas9 ribonucleoprotein (RNP) editing to eliminate the expression of VISTA (V-domain Ig suppressor of T cell activation), a negative immune checkpoint also known as PD-1H. VISTA is highly expressed in the brain tumor microenvironment and normally functions to suppress immune cell activity. Preclinical studies indicate that VISTA-deficient NK cells possess superior tumor-killing capabilities, improved persistence, and a reduced susceptibility to exhaustion compared to wild-type NK cells, potentially offering a novel strategy to overcome the immunosuppressive barriers of solid tumors.
- Other names
- VISTA-edited NK cellsVISTA-deficient NK cells
02
Targets
VISTA
Beyond the preview
Go deeper on VISTA-knockout NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VISTA-knockout NK cells.